Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | Q9HBH1 | 1/20 | 0.38 | |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885605 | 0.90 | KDM1A (0.47) | PLGSSTR3CALCRLITGB1ITGA4 | |
| SCHEMBL4884651 | 0.87 | NTMT1 (0.46) | PLGSSTR3CALCRLITGB1ITGA4 | |
| SCHEMBL4879319 | 0.82 | F7 (0.43) | PLGSSTR3ITGB1ITGA4KLKB1 | |
| SCHEMBL4886967 | 0.81 | CHRNB2 (0.47) | PLGCALCRL | |
| SCHEMBL4887082 | 0.79 | PLG (0.50) | PLGSSTR3KLKB1HDAC1CPB2 | |
| SCHEMBL4888152 | 0.78 | MME (0.49) | — | |
| SCHEMBL4887070 | 0.78 | PLG (0.55) | PLGCTSBKLKB1HDAC1CPB2 | |
| SCHEMBL4887057 | 0.74 | TDP1 (0.38) | PLGCTSBCALCRLITGB1ITGA4 | |
| SCHEMBL4885602 | 0.72 | PLG (0.54) | PLGCTSBKLKB1HDAC1CPB2 | |
| SCHEMBL4885609 | 0.72 | CPB2 (0.51) | PLGSSTR3KLKB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | PLG 3666/4885SSTR3 3679/4885CTSB 1465/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | PLG 551/4885SSTR3 4637/4885CTSB 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.